Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06863129
Recruiting Not applicable

Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Trial

NCT06863129 · tracked via the Priya Life Science Canada tracker
Sponsor
Michelle Ghert, MD
Phase
Not applicable
Started
2025-02-01
Last updated
2026-07-08

Condition(s) studied

Metastatic Bone Disease

Investigational drug(s) / intervention(s)

Internal FixationResection and reconstruction

Internal Fixation: Internal Fixation

Resection and reconstruction: Resection and reconstruction

Study summary

The goal of this clinical trial is to find out if removing and replacing part of the hip bone works better than using metal hardware to stabilize the bone in patients whose cancer has spread to the hip. The main questions are:

1. Does removing and replacing part of the bone work better than just stabilizing it with metal hardware?
2. Does removing and replacing the bone help reduce problems like cancer coming back or the metal hardware breaking?

Researchers will compare two treatments: using metal rods and plates to stabilize the bone (internal fixation) versus removing part of the bone and possibly replacing the hip joint (resection and reconstruction) to see if the second option causes fewer problems.

Participants will:

* Be randomly assigned to one of two groups (internal fixation or resection and reconstruction).
* Have one of the two surgeries based on which group they're in.
* Go to follow-up appointments with the study doctor at 2 weeks, 6 weeks, 4 months, 6 months, 9 months, and 12 months after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Life expectancy of at least 6 months * Lesions in the proximal femur (femoral neck, intertrochanteric region, subtrochanteric region, and combinations thereof) * Low or intermediate risk for perioperative morbidity and/or mortality * No more than 75% and no less than 25% bone loss * Mutual (patient and physician) decision to perform surgical management of an impending or realized pathologic fracture due to MBD of the proximal has been made. Exclusion Criteria: * Lesions isolated to the femoral neck * Lesion with any femoral head involvement * High risk for perioperative morbidity and/or mortality * Multidisciplinary decision that resection of the entire lesion would be indicated

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
University of Colorado Hospital Aurora Colorado Recruiting
Parkview Packnett Family Cancer Institute Fort Wayne Indiana Recruiting
University of Maryland Medical Center Baltimore Maryland Active Not Recruiting
Albany Medical Center Albany New York Active Not Recruiting
University of Cincinnati Medical Center Cincinnati Ohio Recruiting
Good Samaritan Regional Medical Center Corvallis Oregon Withdrawn
Oregon Health and Science University Hospital Portland Oregon Recruiting
Medical University Graz Graz Austria Recruiting
Hospital de Clínicas de Porto Alegre Porto Alegre Rio Grande do Sul Recruiting
Foothills Medical Centre Calgary Alberta Not Yet Recruiting
Mount Sinai Hospital Toronto Ontario Active Not Recruiting
Hôpital Maisonneuve-Rosemont Montreal Quebec Withdrawn
McGill University Health Centre Montreal Quebec Active Not Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06863129 on ClinicalTrials.gov ↗ ← All trials in Canada